Search

Your search keyword '"de Velasco MA"' showing total 72 results

Search Constraints

Start Over You searched for: Author "de Velasco MA" Remove constraint Author: "de Velasco MA"
72 results on '"de Velasco MA"'

Search Results

1. Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.

2. A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin.

3. A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.

4. Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer.

5. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.

6. Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma.

7. Emerging Relationship between the Gut Microbiome and Prostate Cancer.

8. The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome.

9. Gut microbiome and prostate cancer.

10. Performance of Idylla ™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer.

11. Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis.

12. Connecting the Dots Between the Gut-IGF-1-Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis.

13. Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period.

14. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.

15. Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis.

16. Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten -Deficient Prostate Cancer.

17. Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model.

18. Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients.

19. Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis.

20. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer.

21. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

22. HOXA10 expression profiling in prostate cancer.

23. Generation of PTEN‑knockout (‑/‑) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.

24. Prostate cancer immunotherapy: where are we and where are we going?

25. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

26. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

27. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

28. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

29. MEK inhibitors against MET-amplified non-small cell lung cancer.

30. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

31. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.

32. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

33. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

34. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

35. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

36. Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.

37. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

38. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

39. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

40. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.

41. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.

42. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

43. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

44. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

45. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.

46. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.

47. Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.

48. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.

49. MEK inhibitor for gastric cancer with MEK1 gene mutations.

50. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.

Catalog

Books, media, physical & digital resources